BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 21801605)

  • 1. Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
    Su SF; Han F; Zhao C; Huang Y; Chen CY; Xiao WW; Li JX; Lu TX
    Chin J Cancer; 2011 Aug; 30(8):565-73. PubMed ID: 21801605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of locoregionally advanced nasopharyngeal carcinoma treated with intensity modulated irradiation and platinum-based chemotherapy.
    Xu JH; Guo WJ; Bian XH; Wu JF; Jiang XS; Guo YS; He X
    Cancer Radiother; 2013; 17(4):297-303. PubMed ID: 23849438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis.
    Luo Y; Qin Y; Lang J
    Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma.
    Yi J; Huang X; Gao L; Luo J; Zhang S; Wang K; Qu Y; Xiao J; Xu G
    Radiat Oncol; 2014 Feb; 9():56. PubMed ID: 24533569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
    Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J
    Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising treatment outcomes of intensity-modulated radiation therapy for nasopharyngeal carcinoma patients with N0 disease according to the seventh edition of the AJCC staging system.
    Sun Y; Tang LL; Chen L; Li WF; Mao YP; Liu LZ; Lin AH; Li L; Ma J
    BMC Cancer; 2012 Feb; 12():68. PubMed ID: 22336097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
    Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
    Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET/CT-guided dose-painting versus CT-based intensity modulated radiation therapy in locoregional advanced nasopharyngeal carcinoma.
    Liu F; Xi XP; Wang H; Han YQ; Xiao F; Hu Y; He Q; Zhang L; Xiao Q; Liu L; Luo L; Li Y; Mo Y; Ma HZ
    Radiat Oncol; 2017 Jan; 12(1):15. PubMed ID: 28587681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
    Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
    PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone.
    Su SF; Han F; Zhao C; Chen CY; Xiao WW; Li JX; Lu TX
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):327-33. PubMed ID: 21035959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
    Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
    Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up.
    Zhang MX; Li J; Shen GP; Zou X; Xu JJ; Jiang R; You R; Hua YJ; Sun Y; Ma J; Hong MH; Chen MY
    Eur J Cancer; 2015 Nov; 51(17):2587-95. PubMed ID: 26318726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma.
    Ji X; Xie C; Hu D; Fan X; Zhou Y; Zheng Y
    PLoS One; 2013; 8(2):e56208. PubMed ID: 23441169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of long-term survival outcomes and failure patterns of patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: a retrospective analysis.
    Zhao W; Lei H; Zhu X; Li L; Qu S; Liang X
    Oncotarget; 2016 Dec; 7(52):86914-86925. PubMed ID: 27894100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of nasopharyngeal carcinoma patients with T1-2 stage in intensity-modulated radiotherapy era.
    Niu X; Xue F; Liu P; Hu C; He X
    Int J Med Sci; 2022; 19(2):267-273. PubMed ID: 35165512
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical Outcome and Prognostic Factors of Intensity-Modulated Radiotherapy for T4 Stage Nasopharyngeal Carcinoma.
    Luo Y; Gao Y; Yang G; Lang J
    Biomed Res Int; 2016; 2016():4398498. PubMed ID: 27195286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study.
    Wu F; Wang R; Lu H; Wei B; Feng G; Li G; Liu M; Yan H; Zhu J; Zhang Y; Hu K
    Radiother Oncol; 2014 Jul; 112(1):106-11. PubMed ID: 24933452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.